Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major

Susanna Esposito, Emanuela D'Angelo, Cristina Daleno, Francesco Peia, Alessia Scala, Domenico Serra, Nadia Mirra, Carlotta Galeone, Nicola Principi

Research output: Contribution to journalArticle

Abstract

In order to evaluate the immunogenicity, safety, and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major, 31 subjects (19 males; mean age 17.8 ± 8.7 years) with β-thalassemia major and 28 age- and gender-matched healthy controls were enrolled. Four weeks after vaccination, seroconversion rates were about 80% and seroprotection rates 100% in both groups. Three months after vaccination, most of the subjects remained seroconverted and the seroprotection rates were 93.5% among the patients and 100% among the controls. Safety and tolerability were also very good, with no differences between the groups.

Original languageEnglish
Pages (from-to)7825-7828
Number of pages4
JournalVaccine
Volume28
Issue number50
DOIs
Publication statusPublished - Nov 23 2010

Fingerprint

thalassemia
beta-Thalassemia
Pandemics
pandemic
influenza
Human Influenza
Vaccination
Vaccines
vaccination
immune response
vaccines
Safety
seroconversion
gender
MF59 oil emulsion
Seroconversion

Keywords

  • Adjuvants
  • Children
  • MF59
  • Pandemic A/H1N1 influenza virus
  • Pandemic influenza A/H1N1 influenza vaccine
  • Vaccination

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major. / Esposito, Susanna; D'Angelo, Emanuela; Daleno, Cristina; Peia, Francesco; Scala, Alessia; Serra, Domenico; Mirra, Nadia; Galeone, Carlotta; Principi, Nicola.

In: Vaccine, Vol. 28, No. 50, 23.11.2010, p. 7825-7828.

Research output: Contribution to journalArticle

Esposito, Susanna ; D'Angelo, Emanuela ; Daleno, Cristina ; Peia, Francesco ; Scala, Alessia ; Serra, Domenico ; Mirra, Nadia ; Galeone, Carlotta ; Principi, Nicola. / Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major. In: Vaccine. 2010 ; Vol. 28, No. 50. pp. 7825-7828.
@article{784560924d8443cdb2011a1392bb8622,
title = "Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major",
abstract = "In order to evaluate the immunogenicity, safety, and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major, 31 subjects (19 males; mean age 17.8 ± 8.7 years) with β-thalassemia major and 28 age- and gender-matched healthy controls were enrolled. Four weeks after vaccination, seroconversion rates were about 80{\%} and seroprotection rates 100{\%} in both groups. Three months after vaccination, most of the subjects remained seroconverted and the seroprotection rates were 93.5{\%} among the patients and 100{\%} among the controls. Safety and tolerability were also very good, with no differences between the groups.",
keywords = "Adjuvants, Children, MF59, Pandemic A/H1N1 influenza virus, Pandemic influenza A/H1N1 influenza vaccine, Vaccination",
author = "Susanna Esposito and Emanuela D'Angelo and Cristina Daleno and Francesco Peia and Alessia Scala and Domenico Serra and Nadia Mirra and Carlotta Galeone and Nicola Principi",
year = "2010",
month = "11",
day = "23",
doi = "10.1016/j.vaccine.2010.09.058",
language = "English",
volume = "28",
pages = "7825--7828",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "50",

}

TY - JOUR

T1 - Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major

AU - Esposito, Susanna

AU - D'Angelo, Emanuela

AU - Daleno, Cristina

AU - Peia, Francesco

AU - Scala, Alessia

AU - Serra, Domenico

AU - Mirra, Nadia

AU - Galeone, Carlotta

AU - Principi, Nicola

PY - 2010/11/23

Y1 - 2010/11/23

N2 - In order to evaluate the immunogenicity, safety, and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major, 31 subjects (19 males; mean age 17.8 ± 8.7 years) with β-thalassemia major and 28 age- and gender-matched healthy controls were enrolled. Four weeks after vaccination, seroconversion rates were about 80% and seroprotection rates 100% in both groups. Three months after vaccination, most of the subjects remained seroconverted and the seroprotection rates were 93.5% among the patients and 100% among the controls. Safety and tolerability were also very good, with no differences between the groups.

AB - In order to evaluate the immunogenicity, safety, and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major, 31 subjects (19 males; mean age 17.8 ± 8.7 years) with β-thalassemia major and 28 age- and gender-matched healthy controls were enrolled. Four weeks after vaccination, seroconversion rates were about 80% and seroprotection rates 100% in both groups. Three months after vaccination, most of the subjects remained seroconverted and the seroprotection rates were 93.5% among the patients and 100% among the controls. Safety and tolerability were also very good, with no differences between the groups.

KW - Adjuvants

KW - Children

KW - MF59

KW - Pandemic A/H1N1 influenza virus

KW - Pandemic influenza A/H1N1 influenza vaccine

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=78650608963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650608963&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2010.09.058

DO - 10.1016/j.vaccine.2010.09.058

M3 - Article

C2 - 20888873

AN - SCOPUS:78650608963

VL - 28

SP - 7825

EP - 7828

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 50

ER -